Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00384579 · ClinicalTrials.gov registry record · Phase 4

Pilot Study to Assess the Efficacy of Botulinum Toxin B on Pain and Disability in Subjects With Acute Low Back Pain

A Phase 4 study, sponsored by United States Department of Defense.

Terminated
Registry status
Phase 4
Development phase

NCT00384579 is a Phase 4 study that was terminated before completion, run by United States Department of Defense.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00384579, a Phase 4 study, was terminated before completion, sponsored by United States Department of Defense.

TERMINATED
Registry status
Phase 4
Development phase

Study Summary

This study will test the hypothesis that Botulinum toxin B (Myobloc®) treatment reduces pain and disability in subjects suffering from acute low back pain due to an identifiable muscle strain or back trauma occurring 3 to 6 weeks prior to enrollment. The study will also delineate the duration of medication effect and control for any placebo or mechanical trigger-point injection effect by employing a prospective, double-blind, placebo-controlled design.

Interventions

  • DRUG Placebo
  • DRUG Botulinum toxin B

Trial Details

FieldValue
Start Date 2008-02
Est. Completion 2010-08
Phase Phase 4

What the Registry Record Tells You About NCT00384579

The ClinicalTrials.gov registry entry for NCT00384579 describes a study currently listed as terminated, categorized as Phase 4. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is United States Department of Defense, which has 13 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT00384579 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00384579 about?

NCT00384579 is a clinical study titled "Pilot Study to Assess the Efficacy of Botulinum Toxin B on Pain and Disability in Subjects With Acute Low Back Pain". This study will test the hypothesis that Botulinum toxin B (Myobloc®) treatment reduces pain and disability in subjects suffering from acute low back pain due to an identifiable muscle strain or back trauma occurring 3 to 6 weeks prior to enrollment. The study will also delineate the duration of med...

What is the current status of trial NCT00384579?

This trial is currently terminated. It is a Phase 4 study. The study started on 2008-02. Estimated completion is 2010-08.

What interventions are being tested in trial NCT00384579?

The interventions under investigation include: Placebo (DRUG), Botulinum toxin B (DRUG).

Who is sponsoring clinical trial NCT00384579?

This trial is sponsored by United States Department of Defense, which has 13 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.